Literature DB >> 29318968

The Role of DNA Repair Pathways in AML Chemosensitivity.

Elizabeth A Pearsall1,2, Lisa F Lincz1,2,3, Kathryn A Skelding1,2.   

Abstract

BACKGROUND: Defects in DNA repair pathways are causal factors for a plethora of solid tumours, but are only just beginning to be explored in haematological malignancies. Genomic instability, including mutations in DNA sequences, chromosomal aneuploidy, translocations and gene amplifications contribute to the development and progression of AML. Prior DNA damaging agent exposure enhances the risk of developing AML, as does inheritance of genetic syndromes that involve alterations in DNA repair pathways. Furthermore, these same variations are associated with sensitivity and resistance to a range of chemotherapeutics. Taken together, these studies suggest that defects within DNA repair pathways are involved in the pathogenesis and prognosis of AML.
OBJECTIVE: This review summarises the major DNA repair pathways, and presents an overview of current data on DNA damage repair abnormalities in AML as they pertain to the development of resistance and sensitivity to chemotherapeutics in AML. Additionally, the use of drugs that modulate these pathways as new treatments for AML will be explored herein.
CONCLUSION: This review highlights that abnormalities in DNA repair mechanisms in AML cells are potential novel treatment targets for AML patients with disease that is resistant to current therapies. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Acute myeloid leukaemia; DNA repair; base excision repair.; chemosensitivity; direct enzymatic repair; homologouszzm321990recombination; non-homologous end joining; nucleotide excision repair

Mesh:

Substances:

Year:  2018        PMID: 29318968     DOI: 10.2174/1389450119666180110093713

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN: 1389-4501            Impact factor:   3.465


  2 in total

1.  Targeted inhibition of cooperative mutation- and therapy-induced AKT activation in AML effectively enhances response to chemotherapy.

Authors:  Montserrat Estruch; Kristian Reckzeh; Camilla Vittori; Anders Centio; Mina Ali; Sophia Engelhard; Ling Zhao; Kyoung Jae Won; Paul Liu; Bo Torben Porse; Kim Theilgaard-Mönch
Journal:  Leukemia       Date:  2020-12-09       Impact factor: 11.528

2.  Nrf2 overexpression increases risk of high tumor mutation burden in acute myeloid leukemia by inhibiting MSH2.

Authors:  Ping Liu; Dan Ma; Ping Wang; Chengyun Pan; Qin Fang; Jishi Wang
Journal:  Cell Death Dis       Date:  2021-01-05       Impact factor: 8.469

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.